Presentation Title
P-33 Synthesis of Hybrid Heterocyclic Boronic Acids
Presenter Status
Student, Department of Biology
Second Presenter Status
Associate Professor of Chemistry, Department of Chemistry and Biochemistry; Founder & Executive Director of Building Excellence in Science and Technology (BEST)
Preferred Session
Poster Session
Start Date
30-10-2015 2:00 PM
End Date
30-10-2015 3:00 PM
Presentation Abstract
This phase of our research is focused on synthesizing hybrid heterocyclic boronic acids by covalently attaching boronic acids to heterocycles. Synthesis and application of these compounds is an ongoing research project in Professor Murray’s lab over the last few years.
The concept of hybrid compounds from a medicinal chemistry perspective involves covalently combining two or more pharmacophores into a single compound. It is part of a new paradigm and growing realization that most diseases are not simple but complex and require a multi-target, multivalent drug approach.
Boronic acids were previously not viewed as viable functional groups in medicinal chemistry or for pharmaceuticals. However, with FDA approval of boronic acid containing Velcade in 2003 for multiple myeloma they have become accepted pharmacophores showing a diversity of significant biological activity, such as, anticancer, antiviral and antibacterial.
Heterocycles such as rhodanines have also demonstrated a very wide range of biological activity. So, our long-term research goal is to systematically explore the biological activity of hybrid heterocyclic boronic acids. In particular, this project will investigate the antiviral activities of these novel compounds.
P-33 Synthesis of Hybrid Heterocyclic Boronic Acids
This phase of our research is focused on synthesizing hybrid heterocyclic boronic acids by covalently attaching boronic acids to heterocycles. Synthesis and application of these compounds is an ongoing research project in Professor Murray’s lab over the last few years.
The concept of hybrid compounds from a medicinal chemistry perspective involves covalently combining two or more pharmacophores into a single compound. It is part of a new paradigm and growing realization that most diseases are not simple but complex and require a multi-target, multivalent drug approach.
Boronic acids were previously not viewed as viable functional groups in medicinal chemistry or for pharmaceuticals. However, with FDA approval of boronic acid containing Velcade in 2003 for multiple myeloma they have become accepted pharmacophores showing a diversity of significant biological activity, such as, anticancer, antiviral and antibacterial.
Heterocycles such as rhodanines have also demonstrated a very wide range of biological activity. So, our long-term research goal is to systematically explore the biological activity of hybrid heterocyclic boronic acids. In particular, this project will investigate the antiviral activities of these novel compounds.